E-ISSN 2231-3206 | ISSN 2320-4672
 

Review Article 


Newer anti-platelet and anti-thrombotic drugs on the horizon

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi.

Cited by (6)

Abstract
Aspirin is a highly successful antiplatelet drug & still retains its status as the 'front-line' antiplatelet drug; however, increased understanding of platelet biology has led to the development of new antiplatelet drugs that are potentially more effective. Now, more researches in platelet biology has led to this fact that there are more than 90 other metabolic pathways leading to platelet aggregation that are independent of arachidonic acid and therefore not inhibited by aspirin, hence, several more drugs are being developed, aimed at controlling different phases of platelet function such as platelet aggregation & adhesion. The newer drugs now offer potentially greater and more specific control over platelet function. Definitely, these drugs are going to be significantly more expensive than aspirin, and their eventual role in the clinical arena will ultimately depend on both their efficacy and their cost-effectiveness. As we approach the next millennium, it is envisaged that our increased understanding of platelet function, coupled with advances in technology and drug manufacture, will result in even greater improvements in the therapeutic control of platelet thrombus.

Key words: Prasugrel; Ticagrelor; Antiplatelet Drug Therapy; Pathophysiology of Platelet Aggregation


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Ajai Garg
Articles by Anjana Pandey
Articles by Pranab Oza
Articles by Mridul Chaturvedi
on Google
on Google Scholar
Article Statistics
 Viewed: 8809
Downloaded: 2410
Cited: 6


REFERENCES
1. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367(9510):606-17. [DOI via Crossref]   
2. Macchi L, Sorel N, Christiaens L. Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Curr Pharm Des. 2006; 12: 251-58. [DOI via Crossref]    [Pubmed]   
3. FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 2003; 361: 542-44. [DOI via Crossref]   
4. Cattaneo M. Aspirin and clopidogrel resistance: clinical issues. Arteriothrom Vas Biol. 2004; 24: 1980-84. [DOI via Crossref]    [Pubmed]   
5. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J. 2004; 147: 293-30
6. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45(8):1157-64. [DOI via Crossref]    [Pubmed]   
7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel vs. clopigogrel in patients with acute coronary syndromes. N Eng J Med 2007; 357:2001-2015. [DOI via Crossref]    [Pubmed]   
8. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923-32. [DOI via Crossref]    [Pubmed]   
9. VA National Formulary (VANF) Decisions. National drug monograph Prasugrel. Pharmacy Benefits Management - Medical Advisory Panel, Ez-Minutes. 2010;8(2).
10. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2009;361(11):1045-57. [DOI via Crossref]    [Pubmed]   
11. Nawarskas JJ, Clark SM. Ticagrelor: A Novel Reversible Oral Antiplatelet Agent. Cardiol Rev. 2011;19(2):95-100. [DOI via Crossref]    [Pubmed]   
12. Fugate SE, Cudd LA. Cangrelor for Treatment of Coronary Thrombosis. Ann Pharmacother. 2006; 40(5):925-930 [DOI via Crossref]    [Pubmed]   
13. American Journal of Cardiovascular Drugs. Vorapaxar. Am J Cardiovasc Drugs. 2010;10(6):413-418 [DOI via Crossref]    [Pubmed]   
14. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736-47. [DOI via Crossref]    [Pubmed]   
15. Neri Serneri GG, Coccheri S, Marubini E, Violi F; Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25:1845–52.
16. Zafar MU, Ibá-ez B, Choi BG, Vorchheimer DA, Pi-ero A, Jin X, et al. A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010;103(1):205-12. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
17. Lee SW, Park SW, Hong MK, Kim YH, Lee BK, Song JM, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005;46(10):1833-7. [DOI via Crossref]    [Pubmed]   
18. Rasoul S, Ottervanger JP, de Boer MJ, Miedema K, Hoorntje JC, Gosselink M, et al. A comparison of dual vs. triple antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndrome: results of the ELISA-2 trial. Eur Heart J. 2006;27(12):1401-7. [DOI via Crossref]    [Pubmed]   

This Article Cited By the following articles

Developments in inhibiting platelet aggregation based on different design strategies
Future Medicinal Chemistry 2019; 11(14): 1757.

1
 
Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation
European Journal of Medicinal Chemistry 2017; 125(): 197.

2
 
The progress in the research of antiplatelet agents (1995–2017)
Future Medicinal Chemistry 2017; 9(10): 1087.

3
 

2016; (): 383.

4
 
Design, synthesis of novel tryptophan derivatives for antiplatelet aggregation activity based on tripeptide pENW (pGlu-Asn-Trp)
European Journal of Medicinal Chemistry 2015; 102(): 363.

5
 
Progress in the research of GPIIb/IIIa antagonists
Future Medicinal Chemistry 2015; 7(9): 1149.

6
 
How to Cite this Article
Pubmed Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. Newer anti-platelet and anti-thrombotic drugs on the horizon. Natl J Physiol Pharm Pharmacol. 2013; 3(2): 105-110. doi:10.5455/njppp.2013.3.090420131


Web Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. Newer anti-platelet and anti-thrombotic drugs on the horizon. http://www.njppp.com/?mno=9978 [Access: February 15, 2020]. doi:10.5455/njppp.2013.3.090420131


AMA (American Medical Association) Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. Newer anti-platelet and anti-thrombotic drugs on the horizon. Natl J Physiol Pharm Pharmacol. 2013; 3(2): 105-110. doi:10.5455/njppp.2013.3.090420131



Vancouver/ICMJE Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. Newer anti-platelet and anti-thrombotic drugs on the horizon. Natl J Physiol Pharm Pharmacol. (2013), [cited February 15, 2020]; 3(2): 105-110. doi:10.5455/njppp.2013.3.090420131



Harvard Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi (2013) Newer anti-platelet and anti-thrombotic drugs on the horizon. Natl J Physiol Pharm Pharmacol, 3 (2), 105-110. doi:10.5455/njppp.2013.3.090420131



Turabian Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. 2013. Newer anti-platelet and anti-thrombotic drugs on the horizon. National Journal of Physiology, Pharmacy and Pharmacology, 3 (2), 105-110. doi:10.5455/njppp.2013.3.090420131



Chicago Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. "Newer anti-platelet and anti-thrombotic drugs on the horizon." National Journal of Physiology, Pharmacy and Pharmacology 3 (2013), 105-110. doi:10.5455/njppp.2013.3.090420131



MLA (The Modern Language Association) Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. "Newer anti-platelet and anti-thrombotic drugs on the horizon." National Journal of Physiology, Pharmacy and Pharmacology 3.2 (2013), 105-110. Print. doi:10.5455/njppp.2013.3.090420131



APA (American Psychological Association) Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi (2013) Newer anti-platelet and anti-thrombotic drugs on the horizon. National Journal of Physiology, Pharmacy and Pharmacology, 3 (2), 105-110. doi:10.5455/njppp.2013.3.090420131